MINNEAPOLIS — A urologist has been indefinitely barred from inpatient surgery for removing the wrong kidney of one patient and taking a biopsy from another's patient's pancreas instead of a kidney. Dr. Erol Uke has signed the disciplinary ruling from the Minnesota Board of Medical Practice, agreeing that his actions justify the board's discipline.
The ruling said Uke could regain surgical privileges if the board later determines he's competent to do so.
The Star Tribune reported the ruling did not say where the errors happened, just that Uke removed the wrong kidney in March 2008 and performed the erroneous biopsy about four months later.
Uke declined comment when reached at home by The Associated Press.
Monday, January 25, 2010
Increasing Body Mass Index and Kidney Stone Disease
Does obesity lead to an increased risk for the development of kidney stones? Well, yes and no.
An interesting study this month in the Journal of Urology addresses this question. Previous epidemiological works have reported that obesity is a risk factor for kidney stone disease. However, the effect of increasing degrees of obesity on stone formation has yet to be defined. Is the risk linear? The more obese you are, the higher your risk? Is there a cut off?
This study evaluated claims from a 5-year period (2002 to 2006) in a national private insurance database to identify subjects diagnosed with or treated for kidney stones. From a data set of 95,598 patients, subjects were identified by ICD-9 or CPT codes specific to kidney stone disease.
An interesting study this month in the Journal of Urology addresses this question. Previous epidemiological works have reported that obesity is a risk factor for kidney stone disease. However, the effect of increasing degrees of obesity on stone formation has yet to be defined. Is the risk linear? The more obese you are, the higher your risk? Is there a cut off?
This study evaluated claims from a 5-year period (2002 to 2006) in a national private insurance database to identify subjects diagnosed with or treated for kidney stones. From a data set of 95,598 patients, subjects were identified by ICD-9 or CPT codes specific to kidney stone disease.
Conclusions
An obese body mass index is associated with an increased risk of kidney stone disease. However, the magnitude of this risk appears to be stable in the morbidly obese population. Once body mass index (BMI) is greater than 30, further increases do not appear to significantly increase the risk of stone disease.Is Once Daily Renvela Powder Enough?
As dialysis patients know, hyperphosphatemia is a serious concern and a difficult, daily battle. To combat hyperphosphatemia, it takes a careful consideration of dietary intake with every meal or snack.. and the addition of a 'binder'.The 'binders' are phosphorous binders that work in the GI tract to trap dietary phosphorous and help to rid the body of the phosphorous the kidneys are otherwise unable to eliminate in the urine. In addition to the annoyance of needing to be mindful of everything you eat, the pill burden of these binders is often tremendous. It is not uncommon for a hemodialysis patient to take anywhere between 3-5 pills with each meal in an effort to control serum phosphorous to goal < 5.0-5.5.
Accordingly, anything that can decrease the pill burden will be welcomed. Fosrenol has had some degree of success with a chewable tablet taken with each meal. Renvela has followed with an unconventional delivery method of its own, a powder form. The powder comes in the strength of 2.4 grams per packet. This is equivalent to three Renvela pills (800 mg each).
A randomized study conducted at local Winthrop Hospital by Dr Fishbane et al was recently published in the American Journal of Kidney Diseases. After a 2-week phosphate-binder washout, patients were randomly assigned to once-daily sevelamer carbonate powder or thrice-daily sevelamer hydrochloride tablets.
Conclusions
Once-daily administration of sevelamer carbonate powder was not as effective in decreasing serum phosphorus levels as thrice-daily administration of sevelamer hydrochloride tablets. Nevertheless, once-daily sevelamer carbonate powder decreased serum phosphorus levels significantly, reaching the KDOQI phosphorus target in most patients. Therefore, once-daily dosing of sevelamer carbonate may be a reasonable alternative.
Nephrologists Using Social Media Article: Nephrology Times
“I think there was the thought and hope on my side of a marketing and networking platform, but I really haven't found that to be the case because medicine is a very local phenomenon, and Twitter is not.”—Simon Prince, MD
| ||||||||||
Sunday, January 24, 2010
ASN's New Logo
From the ASN website...
ASN: Moving Forward
A major survey conducted in 2008 revealed that ASN members and other stakeholders valued ASN's efforts supporting education, research, and hosting ASN Renal Week. However, many were unaware of ASN's active role addressing concerns in patient care and policy worldwide. As a result, ASN leaders began to evaluate how the Society presents its goals and achievements. In 2009, ASN introduced its tagline, "Leading the fight against kidney disease," and began developing a new logo and visual identity that would embody ASN's ever more active role in the kidney community.
These changes recognize the effort, drive, and results ASN members bring to kidney care and reflect the Society’s evolution in the global kidney community. The new logo is but one of many steps ASN will take between now and its 50th anniversary in 2016 to celebrate the society's commitment to improving lives through advancing research, clinical care, education, and public policy.
What do you think? Is the new logo better or worse than the old one?
Wednesday, January 20, 2010
Hit Movie Avatar May Be Hazardous To Your Health
A Taiwanese man with a history of high blood pressure has died of a stroke that an emergency room doctor says was likely triggered from over-excitement while watching the 3D blockbuster Avatar.
The 42-year-old man, who suffered from hypertension, was rushed to the hospital after he began feeling ill during the screening of the movie earlier this month in the Taiwanese city of Hsinchu, AFP says.
The man identified only as Kuo was unconscious when he got to Nan Men General Hospital where a scan showed that his brain was hemorrhaging, Dr. Peng Chin-Chih, an emergency room doctor, told AFP.
"It's likely that the over-excitement from watching the movie triggered his symptoms," the doctor told AFP.
Kuo died 11 days later from the brain hemorrhage.
The 42-year-old man, who suffered from hypertension, was rushed to the hospital after he began feeling ill during the screening of the movie earlier this month in the Taiwanese city of Hsinchu, AFP says.
The man identified only as Kuo was unconscious when he got to Nan Men General Hospital where a scan showed that his brain was hemorrhaging, Dr. Peng Chin-Chih, an emergency room doctor, told AFP.
"It's likely that the over-excitement from watching the movie triggered his symptoms," the doctor told AFP.
Kuo died 11 days later from the brain hemorrhage.
Friday, January 15, 2010
Wednesday, January 13, 2010
Bystolic, Shot Down by FDA for Heart Failure Indication
Silver Spring, MD (updated January 13, 2010) - An FDA advisory panel voted unanimously not to recommend approval of nebivolol (Bystolic, Forest Laboratories) for the treatment of chronic heart failure. The FDA had already announced it was leaning away from expanding the drug's indication from hypertension, for which it has been available for several years, to include heart failure, for which there are currently only two approved beta blockers in the US.
The main reason both the panel and the FDA opposed the approval: a weak showing in the only trial submitted in its support, the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure (SENIORS).
The drug is already available for heart failure in 71 countries, its advocates said at the hearing.
The 8-0 vote from the Cardiovascular and Renal Drugs Advisory Committee followed a day in which panelists had shown a willingness to overlook certain protocol changes made during the trial that had concerned the FDA.
But there was at least one door left open: most of the panel agreed that there's room for additional nebivolol trials in heart failure, although probably a noninferiority comparison with other beta blockers, not a placebo-controlled trial. "I think most of us agreed in the end that if [the sponsor] wants to pursue this indication," Dr Darren McGuire, an FDA advisory panelist said, "SENIORS could count as one of the two positive trials required."
The main reason both the panel and the FDA opposed the approval: a weak showing in the only trial submitted in its support, the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure (SENIORS).
The drug is already available for heart failure in 71 countries, its advocates said at the hearing.
The 8-0 vote from the Cardiovascular and Renal Drugs Advisory Committee followed a day in which panelists had shown a willingness to overlook certain protocol changes made during the trial that had concerned the FDA.
But there was at least one door left open: most of the panel agreed that there's room for additional nebivolol trials in heart failure, although probably a noninferiority comparison with other beta blockers, not a placebo-controlled trial. "I think most of us agreed in the end that if [the sponsor] wants to pursue this indication," Dr Darren McGuire, an FDA advisory panelist said, "SENIORS could count as one of the two positive trials required."
Tuesday, January 12, 2010
Increased Risk of Colonic Perforation During Colonoscopy in Hemodialysis Patients
Colonoscopies are relatively benign procedures. They are done commonly and can be life saving. Furthermore, aside from "the prep" and anxiety associated with the unpleasant nature of this procedure complications are rare. The most dangerous complication is a perforation of the colon. A perforation of the colon is rare but carries a high mortality rate.
An article in Clinical Gastroenterology and Hepatology takes a look at hemodialysis patients who have undergone colonoscopies. It is a retrospective study of more than 15,000 patients in Japan who had colonoscopies between 2001 and 2008. Approximately 1100 hemodilaysis patients were compared to 14,000 controls. There was 5 colon perforations in the 1100 HD patients, whereas there was only 3 perfs in the 14,000 controls. This was a statistically significant difference and the cause is postulated to be from beta-2 microglobulin deposition in the colon wall.
As is the case with all retrospective studies flaws can be found, and the Japanese HD patient doesnt necessarily equate to the HD patient in the USA. Nevertheless, there may be a higher risk of this potentially lethal complication and certainly something to be aware of.
An article in Clinical Gastroenterology and Hepatology takes a look at hemodialysis patients who have undergone colonoscopies. It is a retrospective study of more than 15,000 patients in Japan who had colonoscopies between 2001 and 2008. Approximately 1100 hemodilaysis patients were compared to 14,000 controls. There was 5 colon perforations in the 1100 HD patients, whereas there was only 3 perfs in the 14,000 controls. This was a statistically significant difference and the cause is postulated to be from beta-2 microglobulin deposition in the colon wall.
As is the case with all retrospective studies flaws can be found, and the Japanese HD patient doesnt necessarily equate to the HD patient in the USA. Nevertheless, there may be a higher risk of this potentially lethal complication and certainly something to be aware of.
Thursday, January 7, 2010
Stage IV CKD in New England Journal of Medicine
Amgen’s, J&J’s Anemia Drugs Face FDA Advisory Review
Jan. 7 (Bloomberg) -- Amgen Inc. and Johnson & Johnson face a review of their top-selling anemia drugs by an advisory panel for the U.S. Food and Drug Administration.The FDA will ask its advisers to evaluate whether lower doses would avoid increased risks of blood clots and heart attacks in patients with chronic kidney disease. The panel was announced in a New England Journal of Medicine commentary.
Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit are known as erythropoiesis-stimulating agents, or ESAs, and are used to boost levels of hemoglobin, an element of red blood cells. Sales of the Amgen anemia drugs fell 15 percent to $5.6 billion in 2008 from their high in 2006 after cardiovascular risks began to emerge in 2007.
“Randomized trials have endeavored to show that using ESAs to raise hemoglobin concentration to higher targets improves clinical outcomes,” Robert Temple, deputy director for clinical science at the FDA’s Center for Drug Evaluation and Research, and his colleagues wrote in the commentary. “Unfortunately and unexpectedly, all results have suggested the opposite.”
The advisory committee meeting “will provide an opportunity to discuss the latest evidence on the benefits and risks of ESAs for patients with chronic kidney disease,” Amgen spokeswoman Emma Hurley said yesterday in an e-mail. The company has already updated prescribing information for its anemia drugs to highlight the risks, she said.
Monday, January 4, 2010
The Top 10 Nephrology Stories of 2009
I hope everyone had a great holiday season. A happy and healthy 2010 to everyone. Before, letting 2009 go... I would be remiss if I didnt put a top ten list up. This one is courtesy of Renal Business Today: 1. Bundling Report Hits the Streets
2. CROWNWeb Delays Full Implementation
3. Healthcare Reform Debates Heat Up
4. The Swine Flu Hits the World
5. Lab Pays Gigantic Sum for Fraud
6. Lufkin Nurse Turns Herself In
7. Dialysis Machine Inventor Dies
8. Dialysis Population/Costs Continue to Rise
9. Aranesp Has Disappointing Results
10. ICD-Roll Out Pushed to 2013
Subscribe to:
Posts (Atom)






